Huntington’s Disease Treatment Market by drug class (Anticonvulsants, Antidepressants, Antidopaminergics, Antipsychotics, Others), route of administration (Oral, Parenteral), distribution channel (Hospitals pharmacies, Retail pharmacies, Online pharmacies) and Geography (North America, Latin America, Europe, Asia Pacific and Middle East and Africa)  

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Huntington’s Disease Treatment Market report gives a comprehensive outlook on across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report on global Huntington’s Disease Treatment market gives historical, current, and future market sizes (US$ Mn) of drug class, route of administration, distribution channel and geographic regions. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of global market. Huntington’s disease is an inherited disorder caused due to degeneration of the nerve cells in the brain. Huntington’s disease signs and symptoms appear in people with 30 to 40 years of age and sometimes disease causes in below 20 years of age group. Most common symptoms of Huntington's disease include difficulties in learning, lack of flexibility, muscle problems, abnormalities in speech, and lack of impulse control. Moreover, depression is the most common psychiatric disorder occurs with Huntington's disease and caused due to damage of brain cells and changes in brain function. There is no permanent treatment for Huntington's disease however, medications are available to manage the symptoms of Huntington's disease. In April 2017, Teva Pharmaceuticals Industries Ltd. received U.S. FDA approval for Austedo tablets used in the treatment of Huntington's disease treatment. In September 2016, Voyager Therapeutics, Inc. collaborated with CHDI Foundation, Inc. (CHDI) foundation to develop novel gene therapy for the treatment of Huntington's disease.

Huntingtons Disease Treatment Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Huntingtons Disease Treatment Market Dynamics

Increase in the prevalence of Huntington’s disease, a rise in R&D activities for the innovation of newer drugs, availability of symptomatic treatment drugs, and rise in the geriatric population is anticipated to fuel the Huntington’s disease treatment market over the forecast period. Moreover, favourable reimbursement policies, a rise in the awareness regarding mental health among key stakeholders, and various pipeline drugs are driving the Huntington’s disease treatment market growth. However, stringent regulatory guidelines and a dearth of treatment options are expected to hinder the growth of Huntington’s Disease Treatment Market

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Huntingtons Disease Treatment Market Segmentation

Drug Class
  • Anticonvulsants
  • Antidepressants
  • Antidopaminergics
  • Antipsychotics
  • Others
  • Oral
  • Parenteral
Distribution Channel
  • Hospitals pharmacies
  • Retail pharmacies
  • Online pharmacies
  • North America
  • Latin America
  • Europe
  • Asia Pacifia
  • Middle East and Africa

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


[urltag url='request-table-of-content']

  • Teva Pharmaceuticals Industries Ltd. (Israel)
  • Valent Pharmaceuticals International Inc. (Canada)
  • Alnylam Pharmaceuticals, Inc. (U.S.)
  • Intellect Neurosciences, Inc. (U.S.)
  • H. Lundbeck A/S (Denmark)
  • F. Hoffmann La Roche Ltd. (Switzerland)
  • QR Pharma, Inc. (U.S.)
  • Voyager Therapeutics, Inc. (U.S.)